Generic Name: tropifexor

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: NAFLD/NASH Medications

Company: Novartis

Approval Status: Experimental

Generic Version Available: No

Experimental Code: LJN452

General Info

Tropifexor is a farnesoid X receptor (FXR) agonist In Phase 2 clinical trials. In these trials, Novartis teamed up with Pfizer, combining various Pfizer compounds with tropifexor. These additional compounds include acetyl CoA-carboxylase (ACC) inhibitor (PF-05221304), a diacylglycerol O-acyltransferase 2 (DGAT2) inhibitor (PF-06865571, and a ketohexokinase (KHK) Inhibitor (PF-06835919).


Dosing Info: N/A

Side Effects


Last Reviewed: February 4, 2019